Clinical Trial Update: Head and Neck Phase III Iressa Versus Methotrexate Refractory: Iressa Versus Methotrexate (IMEX) [Phase 3]

View source ↗

Summary

Phase III trial comparing Iressa (gefitinib) to methotrexate in refractory squamous cell carcinoma of the head and neck; the IMEX study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Iressa (gefitinib)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: AstraZeneca | Conditions: Squamous Cell Carcinoma of the Head and Neck | Phase 3 | Status: COMPLETED